Navigation Links
Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
Date:11/24/2008

LONDON, Nov. 24 /PRNewswire/ -- The European autoimmune disease diagnostics market has demonstrated sustained growth due to advances in detection technology and automation. Active consolidation is occurring in the market, promoting technology and product integration. However, the lack of clarity with regard to reimbursement policies for autoimmune diagnostic tests persists, posing a challenge to market expansion.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), European Autoimmune Disease Diagnostics Market, finds that the market earned revenues of $513.5 million in 2008 and estimates this to reach $722.0 million in 2015.

"The development of novel biomarker panels has accelerated the diagnosis of many autoimmune complications," notes Frost & Sullivan Research Analyst Suraj Ramanathan. "Exhaustive R&D by many universities and research organisations has yielded promising results in the use of multiple biomarkers for autoimmune disease diagnosis."

The ability to screen a patient with multiple biomarkers associated with several autoimmune diseases has been shown to improve the accuracy of the diagnosis and has had a significant positive influence on the autoimmune disease diagnostics market. Such novel biomarker panels will continue to offer an added advantage to physicians in the diagnosis of these complications.

Despite the advances in detection technology, the generalised lack of awareness among the public with regard to autoimmune diseases presents a challenge to market growth.

"Such low levels of awareness may derive from the rarity of many autoimmune complications among the general population," explains Ramanathan. "Many pa
'/>"/>

SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MDV Expands Team Pursuing Advances in Personalized Medicine
2. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
3. New research field promises radical advances in optical technologies
4. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
5. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
6. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
7. New molecular imaging techniques may lead to advances in disease treatment
8. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
9. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
10. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
11. Human Genome Sciences Advances Oncology Portfolio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ntly approved the Promega PowerPlex 16 HS System f...ing DNA records for the National DNA Index System....) -- The FBI recently approved the Promega PowerP...ticipating in, or generating DNA records for, the ...ontains more than seven million profiles and has a...
(Date:11/24/2009)...PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,NASD...al company, today,announced that it has submitted ...cerase alfa, the company,s enzyme replacement ther...cher disease. This is the third marketing,applicat..., with previous,submissions in the United States a...
(Date:11/24/2009)...ber 24 Health Robotics today annou...re with a group of selected,investors. This recent... the,name Health Robotics Canada, Inc. and will ma...oom of the Future concept, which includes the,revo...OFT(TM), and OMM(TM).,Health Robotics Canada Inc. ...
(Date:11/24/2009)...wswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)... the 21st Annual Piper Jaffray Health Care Confere...9, at the New York Palace Hotel. ,, CTI will ...rn Time in Holmes 1 (4th Floor). A live audio webc...w.celltherapeutics.com , and it will also be avail...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
... to 2008 Lineup; Looks to Build Upon 2007 ... Dec. 20 Underscoring its continued commitment,to...reast cancer, the Avon,Foundation today announced ... the first time in Avon Walk history, the series w...ild upon the momentum of a record-breaking,2007 Av...
...ites Recently Initiated To Support Ongoing ...Expected in 2008 from Seven Ongoing or Planned Cli...ajor Disease Indications-, -Revenues Plus Cash On... Advance Programs as Planned-,...ls, Inc. (Nasdaq: PPHM ), a clinical stage biopha...
...nces for Potential Co-Development Opportunity in ...OUTH SAN FRANCISCO, Calif., Dec. 20 ,Exelixis, Inc...mitted a,comprehensive data report for IND candida...istol- Myers Squibb Company now has until the end ...e if it will select the compound for,further devel...
Other Biology Technology:Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 4Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 5Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 2Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 3Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 4
(Date:11/24/2009)...y named 12 new grant recipients for 2009. The awar...rk across a broad spectrum of lupus research. All ...otential to drive scientific discovery to ultimate... systemic lupus. , The 2009 grants go to both ne...ion and include interdisciplinary and highly promi...
(Date:11/24/2009)...dical Toxicology (ACMT) have signed an agreement t...f Medical Toxicology (JMT), the official journal ...iously published by the University of Pennsylvania...an international, peer-reviewed journal, is dedica...al toxicology. The quarterly journal focuses on t...
(Date:11/24/2009).... , The presence of increased body fat, and ... in the blood, hinders the loss and maintenance of...e University of Navarra conducted by Estbaliz Goye.... , The project, entitled "A nutrigenetic and nu...y weight and inflammation," examines how the indiv...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Springer and the American College of Medical Toxicology to work together 2It can be predicted the reaction obese patients will have to a diet 2AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero 53505 1AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero 53505 2New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 1New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 2New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 3New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 1New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 2New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 3New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 4New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 5
...g Quarterly Review of Biology, biologists from Bin...stinct types of laughter ?laughter which is stimul... strategic. , "Laughter that occurs during everyd...s and humorless conversation is now being studied,...he unstated issue is whether such laughter is simi...
...tudy in Science , More than 100 scientists from A...g the genome of the mouse in a joint study lasting... completely overturned geneticists, traditional as...igious journal Science on 2nd September. The gener...ammals is much more complex than was hitherto supp...
...oration Ecology finds that in coastal Louisiana, o...re self-sustaining, and are additionally attractiv...ntial for long-term growth, and contribute to over...ae move in groups and water-borne chemicals stimul...ble to maintain themselves as new recruits settle ...
Other Biology News:Mouse genome much more complex than expected 2
Rabbit Anti-OCT6 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human ABCD4 Polyclonal Antibody, Unconjugated from Atlas Antibodies
... Oligonucleotide) Genome Set and MEEBO (Mouse Exon...tain a collection of open source oligo probes, lar...allowing interrogation of thousands of genes. Deve... Stanford University and UCSF, the sets enable the...
Rabbit Anti-Human XPC Polyclonal Antibody, Unconjugated from Abcam
Biology Products: